What is the Purpose of this Study?
The purpose of this study is to evaluate the use of an investigational drug called simvastatin in women with platinum-sensitive ovarian cancer who are planning to begin treatment with carboplatin and liposomal doxorubicin. Researchers aim to determine the feasibility and effectiveness of a simvastatin intervention during chemotherapy treatment (whether it will help reduce disease progression). Participants will receive simvastatin during their chemotherapy treatment for approximately 6 months, and medical records will be reviewed.
Eligibility
- * Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
- * No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.
Where can I participate?
CS Cancer at Cedars-Sinai Medical Center
More about this Clinical Trial
What is the full name of this clinical trial?
IIT2020-03-Rimel-STOV: Statin Therapy to Reduce Progression in Women with Platinum Sensitive Ovarian Cancer